Martha Groeneveld is an experienced professional in the pharmaceutical sales industry, currently serving as a Patient Access Liaison at Catalyst Pharmaceuticals since December 2018. Previous roles include Regional Account Manager at Coeus Consulting Group - Synergy Pharmaceuticals, where Martha led the product launch of a novel GI therapy, and Account Manager-Consultant at Coeus Consulting Group. Martha also held a position at AstraZeneca as PSS/Respiratory, achieving recognition as the #1 in the business unit and a 2015 Circle of Excellence winner. Additional experience includes Regional Account Manager roles at Santarus, Inc. and Organon Pharmaceuticals, focusing on increasing access and sales for various products across multiple healthcare channels. Martha holds a Bachelor of Science in Business Administration and Management from the University of Oregon Lundquist College of Business.
This person is not in any teams
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.